Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the activity of AVE1625 at the doses of 10 and 40 mg/day in comparison to placebo in patients with mild to moderate Alzheimer Disease: - Safety and tolerability by monitoring of adverse events, clinical laboratories, and ECG - Efficacy by evaluation of cognitive, global, and behavioral parameters
Inclusion criteria
- Mild to moderate Alzheimer Disease